MRI scans to monitor borderline resectable pancreatic cancer treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study uses MRI scans to see how well chemotherapy and radiation work in people with borderline resectable pancreatic cancer – a type where surgery might be possible but is risky. The goal is to find the best way to measure tumor response so doctors can make better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with pancreatic cancer (adenocarcinoma) that is considered borderline resectable (doctors think it might be removable with surgery, but it's very close to major blood vessels).
- You must not have had any prior treatment for this cancer, including surgery, chemotherapy, or radiation.
- You must be in generally good health, as determined by your doctor, with adequate blood counts and liver function.
- You must be willing to undergo MRI scans before and during your treatment to monitor how the tumor responds.
- You cannot be pregnant or breastfeeding, and if you are of childbearing age, you must agree to use effective contraception during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before surgery to shrink the tumor in people with a specific type of pancreatic cancer. The goal is to make surgery more effective and improve outcomes.
This trial tests whether choosing chemotherapy based on a SMAD4 gene change in your tumor works better than the usual approach for pancreatic cancer that can be surgically removed. If you have the gene change, you may get a different chemotherapy combination to improve outcomes.
This study tests giving chemotherapy before surgery for pancreatic cancer that is borderline removable. The chemo is chosen based on your tumor's genetic signature, which may make the treatment more effective and help shrink the tumor enough for successful surgery.
This study tests a new, harmless “disposable” setup for MRI scans to measure how pancreatic cancer treatments affect the body. It may help doctors get more accurate MRI measurements, so treatment response can be assessed better.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This study tests whether using a special MRI scan to guide chemotherapy can help people with pancreatic cancer that is on the edge of being removable. The goal is to shrink the tumor enough for successful surgery.
Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.